论文信息 - Making medicines safer--the need for an independent drug safety board. - 字舞流文

Making medicines safer--the need for an independent drug safety board.

Dexfenfluramine (Redux) was withdrawn from the market in the United States in 1997 amid speculation that millions who used it could have been harmed.1–3 More recently, mibefradil (Posicor) was with...

C. Stein | R. Woosley | C M Stein | A. Wood | A J Wood | R Woosley

[1] F. Messerli,et al. Nifedipine and mortality. Grave defects in the dossier. , 1995, Circulation.

[2] B. Psaty,et al. Nifedipine. Dose-related increase in mortality in patients with coronary heart disease. , 1995, Circulation.

[3] L. Weinrauch,et al. A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation. , 1998, The New England journal of medicine.

[4] P. Corey,et al. Incidence of Adverse Drug Reactions in Hospitalized Patients , 2012 .

[5] M. Angell. Shattuck Lecture--evaluating the health risks of breast implants: the interplay of medical science, the law, and public opinion. , 1996, The New England journal of medicine.

[6] F. Messerli. Case-Control Study, Meta-analysis, and Bouillabaisse: Putting the Calcium Antagonist Scare into Context , 1995, Annals of Internal Medicine.

[7] W. Edwards,et al. Valvular heart disease associated with fenfluramine-phentermine. , 1997, The New England journal of medicine.

[8] J. Vessey,et al. The prevalence of cardiac valvular insufficiency assessed by transthoracic echocardiography in obese patients treated with appetite-suppressant drugs. , 1998, The New England journal of medicine.